PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.15%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-30.87%
G&A reduction while TRVN shows 13.71% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.35%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-30.35%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-2.47%
Both companies reducing D&A. Martin Whitman would check industry patterns.
30.79%
EBITDA growth 1.25-1.5x TRVN's 26.47%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
30.35%
Operating income growth 1.25-1.5x TRVN's 26.10%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
-41.49%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
30.26%
Pre-tax income growth 1.25-1.5x TRVN's 24.76%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
30.26%
Net income growth 1.25-1.5x TRVN's 24.76%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
30.58%
EPS growth 1.25-1.5x TRVN's 24.68%. Bruce Berkowitz would examine sustainability.
33.88%
Diluted EPS growth 1.25-1.5x TRVN's 27.71%. Bruce Berkowitz would examine sustainability.
0.94%
Share count reduction below 50% of TRVN's 0.24%. Michael Burry would check for concerns.
5.92%
Diluted share reduction below 50% of TRVN's 4.06%. Michael Burry would check for concerns.